MediWound

Company Overview

Snapshot

Founded in January 2000, MediWound operates with 51–200 employees and has raised a total of $198.72 million across 8 funding rounds. The company went public on NASDAQ in March 2014, marking a significant milestone in its journey to commercialize enzymatic therapies.

Business overview

MediWound is a global biotechnology company focused on pioneering enzymatic, non-surgical therapies for tissue repair. Its core product, NexoBrid, is an FDA-approved biologic for the enzymatic removal of eschar in thermal burns, marketed across the United States, European Union, Japan, and other international markets. The company is also developing EscharEx, an investigational therapy for chronic wound debridement, aiming to establish a new standard of care in wound management. MediWound operates within the Health Tech & Life Sciences sector, specifically targeting pharmaceuticals and biomaterials for patients.

Strategic signal

In November 2025, MediWound successfully completed the commissioning of its expanded GMP manufacturing facility for NexoBrid. This expansion signals a significant increase in production capacity, indicating strong market demand and the company's commitment to scaling its flagship product. For investors, this suggests a positive outlook for future revenue growth and operational efficiency.

Company Intelligence Q&A

What was a significant recent development for MediWound's manufacturing capabilities?

In November 2025, MediWound successfully completed the commissioning of its expanded GMP manufacturing facility for NexoBrid, indicating increased production capacity for its key product.

What was a key strategic partnership announced by MediWound in October 2023?

In October 2023, MediWound announced a collaboration with 3M on the EscharEx Phase III study, aiming to advance the development of its investigational therapy for chronic wounds.

When did MediWound secure additional funding from the U.S. Department of Defense?

In September 2023, MediWound secured additional funding from the U.S. Department of Defense to advance NexoBrid development for the U.S. Army.

What was the outcome of MediWound's registered direct offering in September 2025?

In September 2025, MediWound announced a $30 million registered direct offering of ordinary shares.

What was a key market expansion for MediWound in September 2025?

In September 2025, MediWound expanded its global reach with marketing approval of NexoBrid in Australia.